Pharma Grids Facing Obstacles Aplenty

By By Derrick Harris, Editor

June 20, 2005

If you haven't had the chance to read The 451 Group's recently released report on Grid adoption in the pharmaceutical industry, don't panic. GRIDtoday editor Derrick Harris spoke with Steve Wallage, director of research at The 451 Group, about it. Although he doesn't give away all the information contained within the report's pages, Wallage does offer great insights into who's using Grids, why some are not and what vendors can do to get a foothold in this potentially large Grid market.



GRIDtoday:
What is the overall conclusion of the report? What does the adoption of Grid in the pharmaceutical market look like?

STEVE WALLAGE: After speaking with several pharmaceutical and biotech firms about their current and future strategies for deploying Grid into the enterprise, The 451 Group found that some of the leading pharmaceutical companies have established significant Grid deployments for drug discovery, but for a majority of them the jury is still out regarding the broader value of Grid computing. A need for high-performance computing makes the pharmaceutical sector a natural adopter of Grids, but we found that compared with other industries, such as financial services, the pharmaceutical sector is behind when it comes to broader deployments.

Some pharmaceutical firms have made great strides in Grid adoption, moving quickly from small Grids, usually based around cycle scavenging, to thousands of devices. The leaders — like Johnson & Johnson and Novartis, for example — are now looking at sharing infrastructure across their companies and putting enterprise IT applications on Grids. But the majority of pharmaceutical firms hear the hype around the early adopters and have yet to identify a compelling reason to adopt Grid technology.

Bottom line: Despite all the claims made around the benefits of Grid deployment, there has yet to be a drug discovered this way.

Gt: Clearly, some pharmaceutical companies are unconvinced of the benefits Grid computing can bring. What are some of the main reasons for this skepticism? What are some of the major obstacles to Grid deployment?

WALLAGE: For those pharmaceutical firms that have not yet invested in Grid technology there are a number of reasons given. The top reason is that there are no compelling applications, meaning the company is not convinced of the benefits of running virtual docking algorithms on a Grid. Another reason is that the current distributed computing architectures work fine. For example, AstraZeneca was an early user of clusters, and it sees no reason to move to Grid technology. In addition, many pharma companies are reluctant to run applications across the PCs of researchers and the greater penetration of laptops was a particular problem.

The biggest obstacle to the pharmaceutical firms has been software licensing. The pharmaceutical firms have looked at various options to address this challenge, from license management to legal action. The ultimate issue is how much pressure the pharmaceutical firms can put on the ISVs in terms of licensing. The situation will improve, but it will probably take another 12 months before more Grid-friendly pricing is really introduced.

Another major obstacle to deployment is cultural issues, since those who make decisions about Grids are often not high up enough in the enterprise decision-making hierarchy, or they run autonomous R&D units. Other obstacles include the challenge of federated data applications and semantic integration. Integrating data that resides in multiple database sources as a result of M&A or the nature of research is a huge headache in this sector. Linking disparate offices is another challenge.

Gt: What are some of the main drivers of adoption?

WALLAGE: Although some pharmaceutical firms had invested in high-performance computing technology for target identification, others have relied on the PCs of researchers. Most companies have used clusters to increase performance, and linking PCs and servers in a Grid was a natural next step for some firms.

Overall, we've identified five main reasons for deploying a Grid:

  • For some early Grid adopters the hardware has come from dedicated server farms. For pharmaceutical firms Grid usage has mostly been about cycle scavenging. It has been about increasing utilization on existing devices.
  • Pharmaceutical companies see Grid technology as an opportunity to reduce hardware costs.
  • A particular weakness for some pharmaceutical firms' R&D operations has been the lack of sharing of information and analysis. Deploying Grid technology across the enterprise would increase cooperation and communication.
  • As with other early Grid users, many of the pharmaceutical companies claim the ability to do things quicker, and also the ability to do more complex analyses.
  • Pharmaceutical companies have been overwhelmed with Grid success stories and ISVs looking for them to try out the technology. In such a competitive and global industry as the pharmaceutical market, none of the major companies wants to risk missing out on a potentially transformational technology. This means even those companies that have yet to invest in a Grid deployment have at least carefully considered such an investment.

Gt: What companies are currently the “shining stars” of Grid adoption within the pharmaceutical market? Are there any companies with unique deployments that might be making news in the future?

WALLAGE: Early adopters such as Johnson & Johnson and Novartis are well ahead of other companies, and are likely to remain so as they seek to adopt Grid technology across all parts of their business. Johnson & Johnson stands out in terms of its vision of Grid technology and the breadth of usage. Meanwhile, Novartis is leading in terms of its PC Grid.

GlaxoSmithKline (GSK) is currently doing some interesting work on data analysis and clinical modeling. Pfizer is as well. Sanofi-Aventis is leading in possible usage of semantic Web work.

Gt: If pharmaceutical companies are all aware of Grid computing, and still many aren't convinced of its value, what can vendors do to get them on board?

WALLAGE: Grid computing vendors face two challenges within the pharmaceutical sector: supporting those users which have established a beachhead for achieving enterprise-wide adoption, and making a better business case for Grid computing technology to the mainstream users. Instead of educating users, vendors need to have strong business arguments to convince them to move forward.

Vendors also need to be aware of some of the obstacles that pharmaceutical companies are facing with deploying Grid technology. Vendors need to be aware of the pain caused by drug discovery software licensing practices, and they need to work with the pharmaceutical ISVs and users to find ways around this issue.

With cultural issues being very complex and far-reaching in the pharmaceutical world, it would benefit vendors to be sympathetic to the needs of individual researchers and to look at best practices on gaining widespread employee support. Many vendors have done very well by selling to certain individuals — typically the head of IT for an R&D unit. This approach will only have limited success in the long term, though, and it has clear operational risks. Vendors need to reach out to central enterprise IT in order to gain wide visibility and support across other departments.

Gt: What Grid vendors are doing the best in selling their wares to in the pharmaceutical industry? How are smaller companies like United Devices and Platform performing versus giants like IBM and HP?

WALLAGE: Overall, the smaller Grid middleware players are the most associated with Grid deployments in the pharmaceutical sector. United Devices is particularly strong and has done a good job of securing sales and awareness among pharmaceutical firms. The company is the main provider to Johnson & Johnson and Novartis, two of the leading pharmaceutical companies in the market and the leaders in deploying Grids across their enterprise. Vendors need to be clear on how to work with, or against, United Devices.

Some other key players include IBM, who is often involved as a systems integrator and is also a close partner to United Devices. Platform Computing also has a number of deployments, while vendors such as DataSynapse and Altair are not yet on the radar.

Gt: It's my understanding that companies in all vertical markets often cite the difficulty of Grid-enabling applications as a major detractor in making the switch to Grid infrastructures. If more ISVs start Grid-enabling popular pharmaceutical apps, will we see a significant rise in adoption?

WALLAGE: It's true that the lack of Grid-enabled applications remains a problem not only in the pharmaceutical sector, but also for Grid computing more generally. In all, about 30 or so ISV applications in this sector are Grid-enabled. The tipping point to a procurement decision is how easily an application can be Grid-enabled, how many applications can be Grid-enabled, and what is the corresponding cost of Grid-enablement versus buying more hardware. Keep in mind that there is also a disconnect between what vendors claim and what users actually see as Grid-enabled.

As far as it causing a significant rise in adoption — it would certainly help. But software licensing issues also need to be addressed at the same time.

Gt: I find it peculiar that Globus is not very popular among the companies profiled, especially considering how popular it is in academic/research settings. Why do you think this is?

WALLAGE: We've found that there are some enterprise IT end users who have looked at the Globus Toolkit, but we have yet to come across any end users who have implemented it in a production environment. From users, we hear that they find Globus complex. The iteration is beyond them, and they don't know what to do with it. The immediate opportunity is for someone to define a stack. Enterprise IT end users say that there are too many Grid middleware stacks and that they would be happy to work with just one moving forward.

To some extent, pharmaceutical firms have chosen Linux and Oracle as de facto standards, but they have not settled on a standard Grid “stack” as such — so there is an opportunity for vendors and open source projects such as Globus to drive the development of this stack.

Gt: If pharmaceutical companies know that the major industry players like Pfizer, GSK and J&J are strong proponents of Grid computing, why haven't the others invested more heavily in order to reduce the competitive advantage these companies are likely experiencing?

WALLAGE: Most pharmaceutical firms have at least assessed Grid computing. All the major pharmaceutical firms continually evaluate Grids but the obstacles we mentioned continue to deter users.

Something very relevant to the potential use of Grid technology is the setup of many pharmaceutical firms' R&D operations. They tend to be autonomous units for two main reasons. One is that multiple units often exist as the result of M&A activity or to harness the strengths of a particular location, such as proximity to a university research department. The pharmaceutical firms want to maintain these units' autonomy in order to keep their effectiveness. The second reason is that the current thinking in the pharmaceutical world is that small R&D facilities are good. For example, GSK is setting up small Centers of Excellence for Drug Discovery, since it believes these groups, which can operate independently of central control, are far more likely to be successful.

It is also relevant to look at the research staff. The lack of IT skills among researchers can be seen in the fact that many get along very nicely in target identification and other drug discovery work without using any sort of computer model, let alone a Grid. For example, Eli Lilly reports that many of its researchers prefer to use tried-and-tested procedures — “wet research” — that don't involve any computerized modeling.

Gt: Where does the pharmaceutical industry stack up against other vertical markets in terms of Grid adoption?

WALLAGE: We found that compared with other vertical markets, such as financial services, the pharmaceutical sector is behind in terms of Grid adoption, especially in the depth and scope of adoption. In the financial services market, investment banks often have a clear roadmap with implementing service-oriented architectures as the ultimate goal. In the pharmaceutical market there are limited deployments, and typically R&D department-led Grid deployments, which limit Grid usage to a few drug discovery applications. Other verticals, with a broader and enterprise-focused view of Grids, are expected to expand their usage over the pharmaceutical users.

Gt: Finally, I'm wondering how what you foresee for the future of Grids in the pharmaceutical industry assuming there are no drug discoveries directly linked to Grid. How would a concrete example of a Grid-based drug discovery change things?

WALLAGE: Pharmaceutical companies are intensely competitive, but at this point, there is still a perception that it is safe to hold off on Grids or run very limited deployments. A Grid-based drug discovery or other compelling evidence of the benefits of Grid would certainly change this perception.

Gt: Is there anything else you would like to add?

WALLAGE: The main issue for many users is whether to spend on software like United Devices, or to get the software “free” and spend on hardware. Life sciences companies will increasingly be turning to open source technology as discovery pipeline budgets are throttled back. Most smaller pharmaceutical firms are already using open source technology in some fashion — either running Linux or running open source algorithms.

For more information about this report, please visit www.the451group.com/intake/gridtoday-jun05.

About Steve Wallage

Steve Wallage is the director of research at New York-based The 451 Group — an independent technology industry analyst company focused on the business of enterprise IT innovation. For more information about the company, please visit its Web site at www.the451group.com.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

Supercomputers Streamline Prediction of Dangerous Arrhythmia

June 2, 2020

Heart arrhythmia can prove deadly, contributing to the hundreds of thousands of deaths from cardiac arrest in the U.S. every year. Unfortunately, many of those arrhythmia are induced as side effects from various medicati Read more…

By Staff report

Indiana University to Deploy Jetstream 2 Cloud with AMD, Nvidia Technology

June 2, 2020

Indiana University has been awarded a $10 million NSF grant to build ‘Jetstream 2,’ a cloud computing system that will provide 8 aggregate petaflops of computing capability in support of data analysis and AI workload Read more…

By Tiffany Trader

10nm, 7nm, 5nm…. Should the Chip Nanometer Metric Be Replaced?

June 1, 2020

The biggest cool factor in server chips is the nanometer. AMD beating Intel to a CPU built on a 7nm process node* – with 5nm and 3nm on the way – has been instrumental to AMD’s datacenter market resurgence. Nanomet Read more…

By Doug Black

Supercomputer-Powered Protein Simulations Approach Lab Accuracy

June 1, 2020

Protein simulations have dominated the supercomputing conversation of late as supercomputers around the world race to simulate the viral proteins of COVID-19 as accurately as possible and simulate potential bindings in t Read more…

By Oliver Peckham

HPC Career Notes: June 2020 Edition

June 1, 2020

In this monthly feature, we'll keep you up-to-date on the latest career developments for individuals in the high-performance computing community. Whether it's a promotion, new company hire, or even an accolade, we've got Read more…

By Mariana Iriarte

AWS Solution Channel

Computational Fluid Dynamics on AWS

Over the past 30 years Computational Fluid Dynamics (CFD) has grown to become a key part of many engineering design processes. From aircraft design to modelling the blood flow in our bodies, the ability to understand the behaviour of fluids has enabled countless innovations and improved the time to market for many products. Read more…

Supercomputer Modeling Shows How COVID-19 Spreads Through Populations

May 30, 2020

As many states begin to loosen the lockdowns and stay-at-home orders that have forced most Americans inside for the past two months, researchers are poring over the data, looking for signs of the dreaded second peak of t Read more…

By Oliver Peckham

Indiana University to Deploy Jetstream 2 Cloud with AMD, Nvidia Technology

June 2, 2020

Indiana University has been awarded a $10 million NSF grant to build ‘Jetstream 2,’ a cloud computing system that will provide 8 aggregate petaflops of comp Read more…

By Tiffany Trader

10nm, 7nm, 5nm…. Should the Chip Nanometer Metric Be Replaced?

June 1, 2020

The biggest cool factor in server chips is the nanometer. AMD beating Intel to a CPU built on a 7nm process node* – with 5nm and 3nm on the way – has been i Read more…

By Doug Black

COVID-19 HPC Consortium Expands to Europe, Reports on Research Projects

May 28, 2020

The COVID-19 HPC Consortium, a public-private effort delivering free access to HPC processing for scientists pursuing coronavirus research – some utilizing AI Read more…

By Doug Black

$100B Plan Submitted for Massive Remake and Expansion of NSF

May 27, 2020

Legislation to reshape, expand - and rename - the National Science Foundation has been submitted in both the U.S. House and Senate. The proposal, which seems to Read more…

By John Russell

IBM Boosts Deep Learning Accuracy on Memristive Chips

May 27, 2020

IBM researchers have taken another step towards making in-memory computing based on phase change (PCM) memory devices a reality. Papers in Nature and Frontiers Read more…

By John Russell

Hats Over Hearts: Remembering Rich Brueckner

May 26, 2020

HPCwire and all of the Tabor Communications family are saddened by last week’s passing of Rich Brueckner. He was the ever-optimistic man in the Red Hat presiding over the InsideHPC media portfolio for the past decade and a constant presence at HPC’s most important events. Read more…

Nvidia Q1 Earnings Top Expectations, Datacenter Revenue Breaks $1B

May 22, 2020

Nvidia’s seemingly endless roll continued in the first quarter with the company announcing blockbuster earnings that exceeded Wall Street expectations. Nvidia Read more…

By Doug Black

Microsoft’s Massive AI Supercomputer on Azure: 285k CPU Cores, 10k GPUs

May 20, 2020

Microsoft has unveiled a supercomputing monster – among the world’s five most powerful, according to the company – aimed at what is known in scientific an Read more…

By Doug Black

Supercomputer Modeling Tests How COVID-19 Spreads in Grocery Stores

April 8, 2020

In the COVID-19 era, many people are treating simple activities like getting gas or groceries with caution as they try to heed social distancing mandates and protect their own health. Still, significant uncertainty surrounds the relative risk of different activities, and conflicting information is prevalent. A team of Finnish researchers set out to address some of these uncertainties by... Read more…

By Oliver Peckham

[email protected] Turns Its Massive Crowdsourced Computer Network Against COVID-19

March 16, 2020

For gamers, fighting against a global crisis is usually pure fantasy – but now, it’s looking more like a reality. As supercomputers around the world spin up Read more…

By Oliver Peckham

[email protected] Rallies a Legion of Computers Against the Coronavirus

March 24, 2020

Last week, we highlighted [email protected], a massive, crowdsourced computer network that has turned its resources against the coronavirus pandemic sweeping the globe – but [email protected] isn’t the only game in town. The internet is buzzing with crowdsourced computing... Read more…

By Oliver Peckham

Global Supercomputing Is Mobilizing Against COVID-19

March 12, 2020

Tech has been taking some heavy losses from the coronavirus pandemic. Global supply chains have been disrupted, virtually every major tech conference taking place over the next few months has been canceled... Read more…

By Oliver Peckham

Supercomputer Simulations Reveal the Fate of the Neanderthals

May 25, 2020

For hundreds of thousands of years, neanderthals roamed the planet, eventually (almost 50,000 years ago) giving way to homo sapiens, which quickly became the do Read more…

By Oliver Peckham

DoE Expands on Role of COVID-19 Supercomputing Consortium

March 25, 2020

After announcing the launch of the COVID-19 High Performance Computing Consortium on Sunday, the Department of Energy yesterday provided more details on its sco Read more…

By John Russell

Steve Scott Lays Out HPE-Cray Blended Product Roadmap

March 11, 2020

Last week, the day before the El Capitan processor disclosures were made at HPE's new headquarters in San Jose, Steve Scott (CTO for HPC & AI at HPE, and former Cray CTO) was on-hand at the Rice Oil & Gas HPC conference in Houston. He was there to discuss the HPE-Cray transition and blended roadmap, as well as his favorite topic, Cray's eighth-gen networking technology, Slingshot. Read more…

By Tiffany Trader

Honeywell’s Big Bet on Trapped Ion Quantum Computing

April 7, 2020

Honeywell doesn’t spring to mind when thinking of quantum computing pioneers, but a decade ago the high-tech conglomerate better known for its control systems waded deliberately into the then calmer quantum computing (QC) waters. Fast forward to March when Honeywell announced plans to introduce an ion trap-based quantum computer whose ‘performance’ would... Read more…

By John Russell

Leading Solution Providers

SC 2019 Virtual Booth Video Tour

AMD
AMD
ASROCK RACK
ASROCK RACK
AWS
AWS
CEJN
CJEN
CRAY
CRAY
DDN
DDN
DELL EMC
DELL EMC
IBM
IBM
MELLANOX
MELLANOX
ONE STOP SYSTEMS
ONE STOP SYSTEMS
PANASAS
PANASAS
SIX NINES IT
SIX NINES IT
VERNE GLOBAL
VERNE GLOBAL
WEKAIO
WEKAIO

Contributors

Tech Conferences Are Being Canceled Due to Coronavirus

March 3, 2020

Several conferences scheduled to take place in the coming weeks, including Nvidia’s GPU Technology Conference (GTC) and the Strata Data + AI conference, have Read more…

By Alex Woodie

Exascale Watch: El Capitan Will Use AMD CPUs & GPUs to Reach 2 Exaflops

March 4, 2020

HPE and its collaborators reported today that El Capitan, the forthcoming exascale supercomputer to be sited at Lawrence Livermore National Laboratory and serve Read more…

By John Russell

‘Billion Molecules Against COVID-19’ Challenge to Launch with Massive Supercomputing Support

April 22, 2020

Around the world, supercomputing centers have spun up and opened their doors for COVID-19 research in what may be the most unified supercomputing effort in hist Read more…

By Oliver Peckham

Cray to Provide NOAA with Two AMD-Powered Supercomputers

February 24, 2020

The United States’ National Oceanic and Atmospheric Administration (NOAA) last week announced plans for a major refresh of its operational weather forecasting supercomputers, part of a 10-year, $505.2 million program, which will secure two HPE-Cray systems for NOAA’s National Weather Service to be fielded later this year and put into production in early 2022. Read more…

By Tiffany Trader

15 Slides on Programming Aurora and Exascale Systems

May 7, 2020

Sometime in 2021, Aurora, the first planned U.S. exascale system, is scheduled to be fired up at Argonne National Laboratory. Cray (now HPE) and Intel are the k Read more…

By John Russell

Summit Supercomputer is Already Making its Mark on Science

September 20, 2018

Summit, now the fastest supercomputer in the world, is quickly making its mark in science – five of the six finalists just announced for the prestigious 2018 Read more…

By John Russell

Fujitsu A64FX Supercomputer to Be Deployed at Nagoya University This Summer

February 3, 2020

Japanese tech giant Fujitsu announced today that it will supply Nagoya University Information Technology Center with the first commercial supercomputer powered Read more…

By Tiffany Trader

Australian Researchers Break All-Time Internet Speed Record

May 26, 2020

If you’ve been stuck at home for the last few months, you’ve probably become more attuned to the quality (or lack thereof) of your internet connection. Even Read more…

By Oliver Peckham

  • arrow
  • Click Here for More Headlines
  • arrow
Do NOT follow this link or you will be banned from the site!
Share This